What is Kraig Biocraft Laboratories In's earnings per share (EPS)?

Kraig Biocraft Laboratories In (KBLB) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kraig Biocraft Laboratories In Financials

KBLB

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Kraig Biocraft Laboratories In (KBLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KBLB FY2025 2026-04-22

Recurring operating cash burn is being bridged by external financing, while a thin asset base supports a heavy liability load.

In FY2025, free cash flow nearly matched operating cash flow, with only $5K of capex separating them; paired with the same pattern in prior years, that says cash use is operational rather than investment-driven. FY2025 financing inflows of $2.47M were enough to offset the $1.79M burn, so liquidity improved even as the underlying deficit remained.

The current ratio stayed below 1x and was only 0.18x in FY2025 even after financing inflows, so new capital improved cash without truly easing short-term strain. With $1.87M of current assets against $10.45M of current liabilities, the company appears dependent on ongoing extensions, conversions, or fresh funding to keep operating flexibility.

The net loss of $3.62M was roughly double the operating cash outflow of $1.79M, so accounting losses are being cushioned by non-cash charges or accruals rather than by self-funding operations. Within operating costs, SG&A at $1.96M outweighs R&D at $166K, which makes the present burn look more like the cost of maintaining the corporate structure than expanding a capital-heavy asset base.

Financial Health Signals

Financial Profile 0/100

Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Kraig Biocraft Laboratories In's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Liquidity

Kraig Biocraft Laboratories In's current ratio of 0.18 is below the typical benchmark, resulting in a score of 0/100. This tight liquidity could limit financial flexibility if cash inflows slow.

Piotroski F-Score Weak

3/9

Kraig Biocraft Laboratories In passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.49x

For every $1 of reported earnings, Kraig Biocraft Laboratories In generates $0.49 in operating cash flow (-$1.8M OCF vs -$3.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-5.9x

Kraig Biocraft Laboratories In earns $-5.9 in operating income for every $1 of interest expense (-$3.4M vs $571K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$3.3M

YoY-9.9%

Kraig Biocraft Laboratories In's EBITDA was -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 9.9% from the prior year.

Net Income

-$3.6M

YoY-6.6%

Kraig Biocraft Laboratories In reported -$3.6M in net income in fiscal year 2025. This represents a decrease of 6.6% from the prior year.

EPS (Diluted)

$0.00

Kraig Biocraft Laboratories In earned $0.00 per diluted share (EPS) in fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.8M

YoY+2.7%

Kraig Biocraft Laboratories In generated -$1.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 2.7% from the prior year.

Cash & Debt

$1.8M

YoY+165.9%

5Y CAGR+17.0%

10Y CAGR+22.3%

Kraig Biocraft Laboratories In held $1.8M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

$166K

YoY+0.8%

5Y CAGR+13.4%

10Y CAGR-9.1%

Kraig Biocraft Laboratories In invested $166K in research and development in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5K

YoY+27.2%

10Y CAGR-18.0%

Kraig Biocraft Laboratories In invested $5K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 27.2% from the prior year.

KBLB Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$166K+0.8%	$164K-30.9%	$238K+34.8%	$176K-10.8%	$198K+123.5%	$88K
SG&A Expenses	$2.0M+12.1%	$1.7M+20.2%	$1.5M+76.2%	$825K-44.8%	$1.5M-57.5%	$3.5M
Operating Income	-$3.4M-9.8%	-$3.1M-17.6%	-$2.6M-23.3%	-$2.1M+23.1%	-$2.8M+39.1%	-$4.5M
Interest Expense	$571K+7.8%	$530K+9.3%	$485K+214.8%	$154K-35.3%	$238K+4245.9%	$5K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.6M-6.6%	-$3.4M-12.2%	-$3.0M+21.1%	-$3.8M+52.2%	-$8.0M-61.8%	-$5.0M
EPS (Diluted)	$0.00	$0.00	$0.00	$0.00	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$9K-85.5%	$64K+167.6%	$24K	N/A	$25K-49.5%	$49K+67.9%	$29K
SG&A Expenses	N/A	$1.2M+248.8%	$344K+11.4%	$309K	N/A	$205K-81.3%	$1.1M+567.8%	$164K
Operating Income	N/A	-$1.4M-124.8%	-$638K-9.9%	-$580K	N/A	-$424K+71.5%	-$1.5M-231.2%	-$449K
Interest Expense	N/A	$144K+1.6%	$142K+1.2%	$140K	N/A	$133K+1.5%	$131K+0.7%	$130K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$1.5M0.0%	-$1.5M-151.6%	-$600K	N/A	-$433K+73.0%	-$1.6M-216.3%	-$508K
EPS (Diluted)	N/A	$0.00	$0.00	$0.00	N/A	$0.00	$0.00	$0.00

KBLB Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$2.6M+70.4%	$1.5M-53.4%	$3.2M-29.3%	$4.6M+51.3%	$3.0M+136.6%	$1.3M
Current Assets	$1.9M+152.4%	$740K-71.2%	$2.6M-35.4%	$4.0M+68.4%	$2.4M+188.7%	$819K
Cash & Equivalents	$1.8M+165.9%	$673K-73.6%	$2.6M-33.9%	$3.9M+64.0%	$2.4M+188.3%	$817K
Inventory	$29K+322.2%	$7K0.0%	$7K+4.6%	$7K	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.6M+9.4%	$9.7M+8.0%	$8.9M+10.5%	$8.1M-2.7%	$8.3M+5.9%	$7.9M
Current Liabilities	$10.4M+8.6%	$9.6M+8.2%	$8.9M+10.1%	$8.1M-1.1%	$8.2M+9.6%	$7.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$8.0M+1.8%	-$8.1M-42.8%	-$5.7M-62.0%	-$3.5M+33.5%	-$5.3M+19.4%	-$6.6M
Retained Earnings	-$56.7M-6.8%	-$53.1M-6.8%	-$49.7M-6.5%	-$46.7M-9.0%	-$42.8M-23.1%	-$34.8M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$2.6M+8.9%	$2.4M+48.1%	$1.6M+20.9%	$1.3M-12.6%	$1.5M-25.7%	$2.0M-8.7%	$2.2M-19.9%	$2.8M
Current Assets	$1.9M+13.9%	$1.6M+95.5%	$839K+85.3%	$453K-38.8%	$740K-40.2%	$1.2M-19.3%	$1.5M-25.5%	$2.1M
Cash & Equivalents	$1.8M+14.3%	$1.6M+99.3%	$785K+97.8%	$397K-41.0%	$673K-43.4%	$1.2M-21.8%	$1.5M-25.7%	$2.0M
Inventory	$29K0.0%	$29K+322.2%	$7K0.0%	$7K0.0%	$7K0.0%	$7K0.0%	$7K0.0%	$7K
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$10.6M+2.4%	$10.3M+2.5%	$10.1M+2.0%	$9.9M+2.2%	$9.7M+2.9%	$9.4M+2.1%	$9.2M+2.0%	$9.0M
Current Liabilities	$10.4M+2.6%	$10.2M+1.5%	$10.0M+2.1%	$9.8M+2.2%	$9.6M+2.9%	$9.3M+2.1%	$9.1M+2.1%	$9.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$8.0M-0.5%	-$8.0M+6.1%	-$8.5M0.0%	-$8.5M-4.0%	-$8.1M-10.8%	-$7.4M-5.5%	-$7.0M-11.7%	-$6.2M
Retained Earnings	-$56.7M-1.4%	-$55.9M-2.8%	-$54.4M-1.4%	-$53.7M-1.1%	-$53.1M-1.6%	-$52.2M-0.8%	-$51.8M-3.2%	-$50.2M

KBLB Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.8M+2.7%	-$1.8M-47.8%	-$1.2M+34.1%	-$1.9M-4.8%	-$1.8M-43.5%	-$1.3M
Capital Expenditures	$5K+27.2%	$4K-33.7%	$6K+27.4%	$5K-94.8%	$97K	N/A
Free Cash Flow	-$1.8M+2.7%	-$1.8M-47.4%	-$1.3M+33.9%	-$1.9M+0.3%	-$1.9M	N/A
Investing Cash Flow	$438K+10431.2%	-$4K+33.7%	-$6K-27.4%	-$5K+99.1%	-$547K	N/A
Financing Cash Flow	$2.5M+7102.3%	-$35K+41.3%	-$60K-101.8%	$3.4M-12.5%	$3.9M+99.6%	$1.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	-$449K+2.7%	-$462K-4.2%	-$443K-2.0%	-$434K+15.2%	-$513K-57.1%	-$326K+36.1%	-$511K-4.3%	-$490K
Capital Expenditures	$2K	$0	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	-$451K+2.3%	-$462K	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	$72K-67.8%	$223K	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	$602K-40.9%	$1.0M+48.1%	$688K+334.9%	$158K	$0+100.0%	-$5K+65.0%	-$15K0.0%	-$15K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KBLB Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-141.2%+84.6pp	-225.8%-132.1pp	-93.7%-9.7pp	-84.0%+182.2pp	-266.3%+123.0pp	-389.2%
Current Ratio	0.18+0.1	0.08-0.2	0.29-0.2	0.49+0.2	0.29+0.2	0.11
Debt-to-Equity	-1.32-0.1	-1.18+0.4	-1.57+0.7	-2.30-0.7	-1.57-0.4	-1.19
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	-64.1%+30.8pp	-94.9%-49.3pp	-45.6%	N/A	-21.4%+51.0pp	-72.4%-54.0pp	-18.3%
Current Ratio	0.18+0.0	0.16+0.1	0.08+0.0	0.05-0.0	0.08-0.1	0.13-0.0	0.17-0.1	0.23
Debt-to-Equity	-1.32-0.0	-1.30-0.1	-1.19-0.0	-1.16+0.0	-1.18+0.1	-1.28+0.0	-1.32+0.1	-1.44
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Note: Shareholder equity is negative (-$8.0M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.18), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Airboss Of Ameri ABSSF

$144.7M

Graphene Mfg Gro GMGMF

$234.5M

Nano One Materia NNOMF

$84.9M

Blue Biofuels Inc BIOF

$46.3M

Greystone Logist GLGI

$3.8M

Frequently Asked Questions

Is Kraig Biocraft Laboratories In profitable?

No, Kraig Biocraft Laboratories In (KBLB) reported a net income of -$3.6M in fiscal year 2025.

What is Kraig Biocraft Laboratories In's EBITDA?

Kraig Biocraft Laboratories In (KBLB) had EBITDA of -$3.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kraig Biocraft Laboratories In's free cash flow?

Kraig Biocraft Laboratories In (KBLB) generated -$1.8M in free cash flow during fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kraig Biocraft Laboratories In's operating cash flow?

Kraig Biocraft Laboratories In (KBLB) generated -$1.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Kraig Biocraft Laboratories In's total assets?

Kraig Biocraft Laboratories In (KBLB) had $2.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kraig Biocraft Laboratories In's capital expenditures?

Kraig Biocraft Laboratories In (KBLB) invested $5K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kraig Biocraft Laboratories In spend on research and development?

Kraig Biocraft Laboratories In (KBLB) invested $166K in research and development during fiscal year 2025.

What is Kraig Biocraft Laboratories In's current ratio?

Kraig Biocraft Laboratories In (KBLB) had a current ratio of 0.18 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

What is Kraig Biocraft Laboratories In's debt-to-equity ratio?

Kraig Biocraft Laboratories In (KBLB) had a debt-to-equity ratio of -1.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kraig Biocraft Laboratories In's return on assets (ROA)?

Kraig Biocraft Laboratories In (KBLB) had a return on assets of -141.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kraig Biocraft Laboratories In's cash runway?

Based on fiscal year 2025 data, Kraig Biocraft Laboratories In (KBLB) had $1.8M in cash against an annual operating cash burn of $1.8M. This gives an estimated cash runway of approximately 12 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Why is Kraig Biocraft Laboratories In's debt-to-equity ratio negative or unusual?

Kraig Biocraft Laboratories In (KBLB) has negative shareholder equity of -$8.0M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Kraig Biocraft Laboratories In's Piotroski F-Score?

Kraig Biocraft Laboratories In (KBLB) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kraig Biocraft Laboratories In's earnings high quality?

Kraig Biocraft Laboratories In (KBLB) has an earnings quality ratio of 0.49x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kraig Biocraft Laboratories In cover its interest payments?

Kraig Biocraft Laboratories In (KBLB) has an interest coverage ratio of -5.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Kraig Biocraft Laboratories In?

Kraig Biocraft Laboratories In (KBLB) scores 0 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.